Identifying the Neural Basis of Capability for Suicide

Sponsor
Unity Health Toronto (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03327129
Collaborator
(none)
90
Enrollment
11
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Since capability for suicide involves overriding potential pain, and the opioid system plays a strong role in controlling pain perception, it follows that capability for suicide may be impacted by the opioid system. The goal of the proposed research is to identify the neural network underlying capability for suicide in order to determine if it can be a target for identifying high-risk individuals and for intervention.

Condition or DiseaseIntervention/TreatmentPhase
  • Procedure: fMRI

Detailed Description

Little evidence exists distinguishing individuals with suicidal ideation (SI) from those at risk for suicidal behaviour, illustrating the need for more comprehensive biomarkers for clinicians to guide their treatment approach and for new treatment avenues. Current theories of suicide have suggested the importance of an individual's capability for suicide in predicting suicide attempt or death. Building on this, Yovell and colleagues (2016) provided important preliminary data that the opioid system affects suicide risk, but the neural mechanisms and their relationship to capability for suicide are unclear. The goal of the proposed research is to identify the neural network underlying capability for suicide using functional magnetic resonance imaging (fMRI) in order to determine if it can be a target for identifying high-risk individuals and for intervention.

Study Design

Study Type:
Observational
Anticipated Enrollment :
90 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Identifying the Neural Basis of Capability for Suicide
Anticipated Study Start Date :
Oct 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

ArmIntervention/Treatment
Healthy Controls

Subjects will have no personal or family psychiatric history and no suicide attempts.

Procedure: fMRI
An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.

Patients with SI

Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >=2).

Procedure: fMRI
An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.

Outcome Measures

Primary Outcome Measures

  1. Neural network underlying acquired capability for suicide [2 weeks]

    Measure the correlation between acquired capability for suicide and brain activity during a pressure pain task using fMRI in patients

Secondary Outcome Measures

  1. Correlation between pain task performance and acquired capability for suicide [2 weeks]

    Assess the association between pain task ratings and acquired capability for suicide in patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria for patients:
  • Age between 18-55

  • Capability of giving informed consent

  • Not currently pregnant or lactating (due to potential confounding of brain activity as a result of differing hormone levels)

Exclusion criteria for patients:
  • Lifetime history of any substance abuse, psychosis

  • Current use of any opioid acting drugs

  • Current use of any prescription pain medication

  • Use of over the counter pain medications within 15 hours of brain scan

  • For daily users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 12 hours of brain scan

  • For as needed users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 2 weeks of brain scan. This is because non-daily use will have more unpredictable effects on brain imaging results than those who are using these medications on a regular basis. The 2 weeks will ensure the drug is not in the system.

  • Medical condition requiring immediate investigation or treatment

  • Participation in experimental treatment trials for the study duration.

Healthy control inclusion criteria: Ages between 18 and 55 years, capable of giving informed consent, not pregnant or lactating, no lifetime history of Axis I/II disorders, no history of antidepressant or mood stabilizer use, no treatment for acute or ongoing medical condition, no use of any over the counter pain medication for at least 15 hours prior to the brain scan.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Unity Health Toronto

Investigators

  • Principal Investigator: Sakina Rizvi, PhD, Unity Health Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Unity Health Toronto
ClinicalTrials.gov Identifier:
NCT03327129
Other Study ID Numbers:
  • SRO-01
First Posted:
Oct 31, 2017
Last Update Posted:
Oct 6, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 6, 2021